Organisation paid for research Program year 2025 Source: CMS Open Payments

Children's Healthcare of Atlanta Inc

Neither a doctor nor a teaching hospital

Research payments

$660,197

263 payments

Through program year 2025, Children's Healthcare of Atlanta Inc is reported as receiving $660,197 in research payments, across 263 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$136,142	91
2024	Research	$191,070	126
2023	Research	$64,590	9
2022	Research	$99,582	25
2021	Research	$168,813	12

Breakdown

Who paid Research payments · program years 2021–2025

Aimmune Therapeutics, Inc. $327,464 42 payments
Jazz Pharmaceuticals Inc. $124,572 77 payments
Mannkind Corporation $52,637 92 payments
Swedish Orphan Biovitrum AB $45,208 18 payments
Chiesi USA, Inc. $43,662 13 payments
CSL Behring $26,739 8 payments
Geron Corporation $14,000 2 payments
Cerus Corporation $12,629 3 payments
HEMA Biologics, LLC $5,500 1 payment
BioMarin Pharmaceutical Inc. $4,000 4 payments

Studies the money was for Research payments · program years 2021–2025

Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (Poseidon) $136,073 9 payments
Arc008 $100,323 14 payments
A Multicenter, Open-Label, Long-Term Safety Study of AR101 Characterized Oral Desensitization Immunotherapy in Subjects Who Participated in A Prior Ar101 Study $91,068 19 payments
A Phase 3 Randomized Trial for Patients With de Novo Aml Comparing Standard Therapy Including Gemtuzumab Ozogamicin (Go) to Cpx-351 With Go, and the Addition of the Flt3 Inhibitor Gilteritinib for Patients With Flt3 Mutations $87,000 4 payments
Inhale-1 $52,637 92 payments
Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with PL (METRE-PL) $43,662 13 payments
Sobi.Emapalumab-105 $42,023 17 payments
A Randomized, Double-Blind, Placebo-Controlled, Multisite, Phase 3 Study to Investigate the Efficacy and Safety of Cannabidiol Oral Solution (Gwp42003-P) in Children and Adolescents With Epilepsy With Myoclonic-Atonic Seizures $36,660 14 payments
A Phase 1 Pilot Study to Evaluate the Safety and Feasibility of Gene Therapy With CSL200 (Autologous Enriched CD34+ Cell Fraction That Contains CD34+ Cells Transduced With Lentiviral Vector Encoding Human -GlobinG16D and Short-Hairpin RNA734) in Adult Subjects With Severe Sickle Cell Disease $25,695 7 payments
Pepn2312 $14,000 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.